New Toxicity Identified with Kinase Inhibitors and Anti-PD-L1 Agents
Adding these inhibitors to immunotherapy increases the risk of thyroid dysfunction, especially in patients who already have autoantibodies against this organ.
Scientists from Nagoya University have found that the use of tyrosine kinase inhibitors (TKIs) in combination with anti-PD-L1 drugs is associated with greater thyroid toxicity compared with anti-PD-L1 monotherapy. In more than 700 patients who received either regimen, the incidence of … + read more
Approach to Thyroid Cancer – Handbook of Oncological Pharmacology
According to the Spanish Society of Medical Oncology (SEOM), about 6,000 new cases of thyroid cancer will be diagnosed in 2023. + more
Thyroid cancer survival increases by 15%
Thyroid cancer is the ninth most common tumor in the world; an estimated 6,000 new cases will be diagnosed in Spain in 2023. + more
Positive results of sapanissertib and ziv-aflibercept in patients with advanced solid tumors
Combination therapy provides 78% disease control in patients with multiple prior treatments and metastatic disease. + read more
PFAs are a possible risk factor for thyroid cancer
A link has been found between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk of thyroid cancer, thus documenting what was until now a hypothesis. + read more
New PET tracer improves detection of medullary thyroid cancer lesions
CMT is one of the rarest forms of thyroid cancer, accounting for approximately three percent of all cases. + read more
Improved survival with anlotinib in resistant lung cancer
Antiangiogenic therapy in patients with osimertinib-resistant tumors is more effective than immunotherapy or chemotherapy. + read more